SKP2 and AL amyloidosis: Malek et al., identified a completely unique Skp2 inhibitor, DT204, which reduces Skp2 binding to Cullin-1 and Commd1 and that, in co-treatment with BTZ, overcomes drug resistance in multiple myeloma [52].